# US 11,992,515 B2 · Method for treating pulmonary fibrosis using S100A3 protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,992,515 B2
- Document ID: US11992515B2
- Status: Granted
- Kind: B2
- Application number: 17/080,268
- Filed: 2020-10-26
- Published: 2021-02-25
- Granted: 2024-05-28
- Earliest claimed: 2018-10-09
- Assignees: King Faisal Specialist Hospital & Research Centre
- Applicants: King Faisal Specialist Hospital & Research Centre
- Inventors: Eid Abdullah Al Mutairy; Mohammed Khalid; Futwan Al-Mohanna
- Web page: https://patentgrep.com/patent/US11992515B2

## CPC

- A61K 38/1738: {Calcium binding proteins, e.g. calmodulin}
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 11/00: Drugs for disorders of the respiratory system
- C07K 14/4728: {Calcium binding proteins, e.g. calmodulin}
- C12N 15/52: Genes encoding for enzymes or proenzymes
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- C12Q 1/6813: Hybridisation assays
- C12Q 1/6827: for detection of mutation or polymorphism
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention is directed to a method for diagnosing and treating a pulmonary lung disease by detecting a mutant S100A3 protein associated with pulmonary lung disease and by treating a subject with a functional S100A3 protein.

## Claims

### Claim 1

A method for treating pulmonary fibrosis in a subject carrying missense variant rs13835706 comprising detecting a mutant S100A3 polynucleotide comprising SEQ ID NO: 3 in a biological sample from the subject and administering a therapeutic agent treating the subject for pulmonary fibrosis.

### Claim 2 (depends on 1)

The method of claim 1 that comprises detecting a polynucleotide that encodes the mutant S100A3 protein using probes and/or primers that selectively recognize the polynucleotide comprising rs138355706 (229C>T).

### Claim 3 (depends on 1)

The method of claim 1, further comprising detecting whether the subject is homozygous for a polynucleotide encoding a mutant S100A3 protein, or heterozygous for a polynucleotide encoding a mutant S100A3 protein.

### Claim 4 (depends on 1)

The method of claim 1, wherein said therapeutic agent is an anti-inflammatory drug.

### Claim 5 (depends on 1)

The method of claim 1, wherein said therapeutic agent is an inhaled steroid.

### Claim 6 (depends on 1)

The method of claim 1, wherein said therapeutic agent is a bronchodilator.

### Claim 7 (depends on 1)

The method of claim 1, wherein said therapeutic agent is an NSAID.